Navigation Links
Study suggests existing drugs may be useful in treating brain tumors
Date:10/16/2007

Oct. 15, 2007 -- Scientists have shown how developing brain tumors can turn an encounter with a signaling molecule from a fatal experience for the tumor cells into a cue for their own growth and multiplication.

Researchers at Washington University School of Medicine in St. Louis found the transformation relies on at least two other molecules that can be modified with existing drugs, opening the possibility that they may be able to use the established drugs to treat brain tumors.

The study, reported in Cancer Research, was conducted in a mouse model of neurofibromatosis type 1 (NF1), a genetic condition that leads to the development of benign and malignant tumors.

"In addition to opening up several new, exciting possibilities for brain tumor treatment both in NF1 and generally, this research is leading to what could be a very important set of insights into fundamental mechanisms of tumor formation," says the paper's senior author, Joshua Rubin, M.D., Ph.D., assistant professor of pediatrics, neurology and of neurobiology.

Rubin studies general pediatric brain tumor development. His colleague and co-author David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology, specializes in NF1 research and directs the University's Neurofibromatosis Center, where the research took place.

The signaling molecule that scientists studied, CXCL12, binds to a receptor called CXCR4 on the surfaces of brain cells. Other researchers first identified CXCR4 while searching for receptors targeted by HIV during infection. Initially, they assumed that CXCR4's primary responsibility was controlling the movement of immune system cells. However, when they genetically disabled the receptor in mice, it had catastrophic effects on organ systems throughout the body. Further study showed the receptor was associated not only with cell movement but also with cell survival and replication.

"All of those things are also changed in cancers: canc
'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University in St. Louis
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...na, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray ...ing developer, manufacturer and,marketer of medica...unaudited,financial results for the third quarter ...Highlights for Operations as of September 30, 2009...1 million, an increase of, 3.1% over the thi...
(Date:11/9/2009)...ks President Obama,s promise to not expand abortio... Bishops still concerned for poor, elderly ,, ...inal Francis George of Chicago, president of the U...d the November 7 decision of the U.S. House of Rep...oney from paying for elective abortions. ,, In...
(Date:11/9/2009)... Studying Genetic Variance Across the World is C... (Vocus) November 9, 2009 --...xtraordinarily valuable when analyzing and interpr...ics study that scanned the genomes of 4,000 peopl...rences, Drs. Chao Tian and Michael F. Seldin of th...
(Date:11/9/2009)...new cells regained sexual function, study says,...Researchers were able to restore sexual function t...le tissue in the lab and implanting it, a new stud...ys off, researchers say the technique could one da...men. , "We were able to show the tissue was abl...
(Date:11/9/2009)... Course, to be Offered in April 2010, Provides F... Cambridge, MA (Vocus) November 9,...an Rights (PHR) first inspected a suspected mass ...d he would need a team of experts to help interpre...perly was a key first step in securing evidence of...
Breaking Medicine News(10 mins):Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:News from the November/December Issue of Molecular Medicine 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4
...N.J., Dec. 12 Alfacell Corporation (Nasdaq: AC...president, chief financial officer and corporate s...s of today. Mr. Kenyon will remain on the board o... Kenyon has accepted a full time position as execu...
...ass., Dec. 12 Millennium Research Group (MRG) ana...ished G lobal Markets for Hyaluronic Acid Viscos...fer extensive expertise on the recent FDA premarke...s available to comment on: , , , , ...
..., Dec. 12 Ogilvy Public Relations Worldwide (Ogi... announced today that it has been awarded a five-y...with the National Cancer Institute (NCI), Office o...,s life sciences consulting subsidiary, Feinstein ...
...hase 3 Program Expected to Begin in December - , ...rmaceuticals, a division of Wyeth (NYSE: WYE ), ...inical trial of neratinib (HKI-272) in women with ...the ErbB-2 receptor (also known as HER-2 or Neu). ...
...s not sure whether one causes the other, or one is...2 (HealthDay News) -- Adults who have panic disord...t attacks and heart disease, but not heart-related...than 347,000 adults without the condition. , Peopl...
...ec. 12 The Female Health Company (NYSE Alternex...Administration,s (FDA) Obstetrics and Gynecology D...at the company,s second-generation female condom, ...ondition that the FC2 Female Condom,s instructions...
Other Medicine News:Health News:Alfacell Announces Management Update 2Health News:Alfacell Announces Management Update 3Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:Panic Disorder Linked to Higher Risk of Heart Disease 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5
(Date:11/9/2009)..., NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ ...ay announced its schedule of events at the 38th an...logy (AAGL), which runs from November 15-19 in Orl...will be presented featuring the Company,s Urology/...truction systems and mid-urethral sling systems us...
(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCa...E: AOB ), ("the Company" or "AOBO"), a pharmaceut... the development, manufacture and,commercializatio...unter ("OTC"),products, today announced that it pl...s on Monday, November 16, 2009, after the market c...
(Date:11/9/2009)..., SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall...today reported financial results for the third qua...d a lower net loss allocable to common stockholder...r $0.38 per share, compared to a net loss allocabl...008 of $56.2 million, or $0.76 per share, and a ne...
Breaking Medicine Technology:Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Exercise 30 Minutes a Day 3F Who Knew 21 58468 1Exercise 30 Minutes a Day 3F Who Knew 21 58468 2Boston University School of Medicines black womens health study receives 249 1 million award 58465 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 2Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 3Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 4
EBI OsteoGen™-M (Mesh Cathode)
Interference Screws
...crew is indicated for graft fixation in Orthopaedi...s with bone-patellar tendon-bone or soft tissue au...es easy and atraumatic insertions with excellent g...-Reinforced 96L/4D copolymer combines optimal stre...
PHANTOM SofThread Cannulated Interference Screws
Medicine Products: